The Latest Cardiac and Vascular News
FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today announced the formation of its Scientific Advisory Board (SAB). The SAB is expected to provide strategic guidance as well as scientific, clinical trial, and therapeutic area expertise as Retension advances RTN-001 in clinical development in the ongoi
Company Engaged with Interventional Radiology Community at Leading Global Congress in CopenhagenCOPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today highlighted its participation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, held at the Bella Center Copenhagen. Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA) System to interventional radiologists and healthcare professionals from around the world, providing an opportunity to engage with the global medical community and demonstrate the Company’s technology and approach to minimally invasive ablation. Baird Medical’s MWA System is designed to deliver precise and controlled ablation and features temperature control technology, stable 2.45 GHz microwave energy delivery, and a range of specialized probes designed to support different clinical applications. “Participating in CIRSE is an important part of Baird Medical’s continued engagement with the global medical community and reflects the international reach we have built across our business,” said Haimei Wu, Chairwoman and Chief Executive Officer of Baird Medical. “As we continue to strengthen our presence in the U.S. and across global markets, conferences like CIRSE provide valuable opportunities to connect with physicians from around the world, share our technology and deepen the relationships that support the broader adoption of minimally invasive treatment solutions.” Baird Medical’s participation at CIRSE 2026 reflects the Company’s broader commitment to advancing minimally invasive treatment technologies and strengthening its engagement with physicians and healthcare institutions globally. As the Company continues to expand its presence internationally, most recently in Pakistan, Vietnam, and Argentina, Baird Medical remains focused on providing reliable, precise and versatile technologies designed to support physicians and improve treatment options for patients. About Baird Medical Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system. Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact: Lee RothBurns McClellan for Baird MedicalLroth@burnsmc.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7e99f8d1-7274-40cd-813c-fe0e717dc3ad
Transaction positions Jaguar to advance the Laminar program and its differentiated approach to left atrial appendage closure for patients with non-valvular atrial fibrillation SANTA ROSA, Calif., Sept. 11, 2026 /PRNewswire/ — Jaguar LAA, Inc. (“Jaguar”), a privately held medical device…
Aalborg University-led research, published in PLOS Digital Health, found the CADScor System’s acoustic sensing platform identified heart failure with diagnostic accuracy comparable to a leading blood test, and with significantly fewer false positives OKLAHOMA CITY, Sept. 11, 2026…
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro
RODEN, Netherlands–(BUSINESS WIRE)–Interventional Medical Device Solutions (IMDS), a specialty catheter company developing purpose-built solutions for complex PCI, CHIP, and CTO procedures, today announced the U.S. launch of NHanceIT™, an over-the-wire, single-lumen microcatheter built on proprietary Skeleton Backbone™ technology. Engineered to improve lesion crossing in challenging coronary anatomy, NHanceIT is part of the IMDS portfolio designed to address distinct procedural challenges thr
SAN FRANCISCO–(BUSINESS WIRE)–Epsilon Health (“Epsilon”), the AI-native radiology practice reinventing how radiology is delivered, today emerged from stealth with $27.6 million in funding led by AlleyCorp, with participation from Uncork Capital, Renegade Partners, SemperVirens, and Jack Altman, who invested while serving as Managing Partner at Alt Capital. Epsilon is tackling one of the most urgent crises in American healthcare.Medical imaging is a foundational pillar of the U.S. healthcare sy
— Advancing global expansion, pediatric robotic surgery and telesurgery — — Growing SSi Mantra installations, procedures and utilization — FORT LAUDERDALE, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) — via IBN — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provided an update on the Company’s continuing progress and milestones. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Our advanced, cost-effective SSi Mantra surgical robotic system (the “SSi Mantra”) is benefitting lives globally, one patient at a time, from a 45-day old baby needing kidney surgery in India to a cardiac patient in Sri Lanka. Our progress in democratizing access to state-of-the-art surgical robotic care continues to be reflected in growing SSi Mantra installations, procedures and utilization.” Recent Company Progress and Milestones: Global Expansion Colombia. On July 29, 2026, Dr. Sudhir Srivastava officially launched the robotic cardiac surgery program at La Fundación Cardiovascular de Colombia (FCV) in Bucaramanga, Colombia, performing the country’s first Totally Endoscopic Beating-Heart Bypass Surgery using the SSi Mantra surgical robotic system. Sri Lanka. On August 23, 2026, Kings Hospital Colombo installed the first SSi Mantra surgical robotic system in Sri Lanka, marking the official launch of the medical center’s robotic surgery program. Following its installation at Kings Hospital, the SSi Mantra has been utilized to perform the country’s first robotic-assisted cardiac surgery and over 25 other robotic surgeries within the first three weeks of operation. Global Installed Base. With the installation in Sri Lanka, the SSi Mantra’s global installed base now spans 12 countries, including a leading presence in the Company’s immense home market of India. US and EU Regulatory Review. Looking ahead, SS Innovations expects that the U.S. Food and Drug Administration will complete its review of the Company’s 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027 and believes that a European Union CE marking certification can be obtained by the end of 2026. Pediatric Robotic Surgery Intricate Robot-Assisted Pediatric Surgery. On August 14, 2026, the Company’s SSi Mantra surgical robotic system and 5-millimeter instrumentation were utilized by Dr. M. Ramalingam to perform a robotic pyeloplasty on a 45-day-old baby at Hindusthan Hospital in Coimbatore, India. The infant recovered rapidly after successful completion of the complex yet minimally invasive kidney procedure. This accomplishment represents another proof point for the SSi Mantra’s capabilities in pediatric robotic surgery, which involves the smallest patients and requires superior precision and control during suturing and cutting, among other surgical tasks. Cumulative Pediatric Surgeries. As of August 31, 2026, a total of 258 pediatric robotic surgeries have been completed with the SSi Mantra. Robotic Telesurgery Longest-Distance Telesurgery. On July 29, 2026, a team of surgeons led by Dr. Sudhir Srivastava utilized the SSi Mantra to perform a successful robotic telesurgery between Colombia and India, spanning more than 13,600 miles (22,000 kilometers) of fiber network distance and eclipsing the previous longest-distance telesurgery record also held by the Company. The telesurgery, a robotic sleeve gastrectomy, was performed remotely from Hospital Internacional de Colombia in Bucaramanga, Colombia on a patient located at Mohak Bariatrics and Robotics in Indore, India. Expanding Ecosytem in India. On August 9, 2026, Ahmedabad, India-based Shalby Hospital joined an expanding ecosystem of healthcare institutions utilizing the SSi Mantra to perform robotic-assisted telesurgery. Three surgical procedures were successfully performed remotely from SS Innovations’ headquarters in Gurugram, India, more than 590 miles (950 kilometers) from the patients at Shalby Hospital. Launch of Telesurgery in the Philippines. On September 5, 2026, the SSi Mantra was used to perform the first telesurgery within the Philippines between Pampanga and Cotabato, a distance of approximately 1,070 miles (1,710 kilometers). Cumulative Telesurgeries. As of August 31, 2026, a total of 188 robotic telesurgeries have been completed with the SSi Mantra. Increasing Utilization and Scale 50 Robot-Assisted Surgeries in a Single Day. On August 15, 2026, the surgical team at Mohak Bariatrics and Robotics in Indore, India utilized five separate SSi Mantra systems to successfully complete 50 robotic general surgery procedures in a single day, demonstrating the robustness of the Company’s technology. Practice and Hospital Milestones. Numerous practices and hospitals across India and abroad are surpassing the 200+, 100+ and 50+ procedure milestones with the SSi Mantra, indicating growing utilization and ability to scale. Growing Installations and Procedures More than 14,000 Successful Procedures. As of September 8, 2026, the SSi Mantra cumulative installed base totaled 238, up 42% from 168 at the end of 2025 and the number of multi-specialty procedures completed with the SSi Mantra totaled 14,103, up 79% from 7,885 at the end of 2025. Broad Pool of Surgeon Users. To date, approximately 1,500 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of surgical procedures. About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi MantraThe SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures. Forward Looking StatementsThis press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investor Contact:The Equity Group Kalle Ahl, CFA T: (303) 953-9878 kalle.ahl@theequitygroup.com Devin Sullivan, Managing Director T: (212) 836-9608devin.sullivan@theequitygroup.com Media Contact:RooneyPartners LLCKate BarretteT: (212) 223-0561kbarrette@rooneypartners.com Corporate Communications: IBNAustin, TexasIBN.Ai512.354.7000 OfficeEditor@IBN.Ai
New research builds on earlier findings showing HFSA’s OMT-HF program improves clinician confidence in delivering guideline directed medical therapy WASHINGTON, Sept. 10, 2026 /PRNewswire/ — New research published in the Journal of Cardiac Failure provides additional evidence that…
HOUSTON–(BUSINESS WIRE)–XCath Robotics, a medical device company advancing endovascular surgical robotics, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Iris Surgical Robotic System for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. The FDA’s Breakthrough Devices Program is designed to support the development of medical devices that have the potential to provide more effective treatment f
